The optimal composition of influenza vaccines subject to random production yields

Manufacturing and Service Operations Management

Volumn 12, Issue 2, 2010, Pages 256-277

  Cho, Soo Haeng ^a  

^a CARNEGIE MELLON UNIVERSITY   (United States)

Author keywords

Dynamic programming; Health care management; Supply chain management

Indexed keywords

ADVISORY COMMITTEE; BIOLOGIC PRODUCTS; CARE MANAGEMENT; INFLUENZA VACCINES; OPTIMAL COMPOSITION; OPTIMAL DYNAMICS; OPTIMAL POLICIES; OPTIMAL THRESHOLD; PARAMETER VALUES; PRODUCTION TIME; PRODUCTION YIELD; SOCIAL WELFARE; VIRUS STRAINS;

DECISION MAKING; DYNAMIC PROGRAMMING; HEALTH RISKS; OPTIMIZATION; PRODUCTION; SUPPLY CHAINS; VACCINES; VIRUSES;

SUPPLY CHAIN MANAGEMENT;

EID: 77952207482     PISSN: 15234614     EISSN: 15265498     Source Type: Journal    
DOI: 10.1287/msom.1090.0271     Document Type: Article

References (37)

1. Anderson, R. M., R. M. May. 1991. Infectious Diseases of Humans: Dynamics and Control. Oxford University Press, New York.
2. Andreasen, V., J. Lin, S. A. Levin. 1997. The dynamics of cocirculating infiuenza strains conferring partial cross-immunity. J. Math. Biology 35(7) 825-842.
3. Bailey, N. T. J. 1975. The Mathematical Theory of Infectious Diseases and Its Applications. Grifin, London.
4. Brito, D. L., E. Sheshinski, M. D. Intriligator. 1991. Externalities and compulsory vaccinations. J. Public Econom. 45(1) 69-90.
5. Centers for Disease Control and Prevention. 2007a. Influenza (fiu). Retrieved October 20, 2007, http://www.cdc.gov/fiu.
6. Centers for Disease Control and Prevention (CDC). 2007b.2007-2008 influenza vaccine production and distribution. http://www2a.cdc.gov/podcasts/ media/pdf/PanFluVodcast9-07.pdf.
7. Centers for Disease Control and Prevention (CDC). 2008. Seasonal influenza vaccine supply for the U.S. 2008-09 infiuenza season. Retrieved September 26, 2008, http://www.cdc.gov/fiu/about/qa/vaxsupply.htm.
8. Chick, S. E., H. Mamani, D. Simchi-Levi. 2008. Supply chain coordination and infiuenza vaccination. Oper. Res. 56(6) 1493-1506.
9. Cohen, M. A., J. Eliashberg, T. Ho. 1996. New product development: The performance and time-to-market tradeoff. Management Sci. 42(2) 173-186.
10. Deo, S., C. J. Corbett. 2009. Cournot competition under yield uncertainty: The case of the U.S. influenza vaccine market. Manufacturing Service Oper. Management 11(4) 563-571.
11. Earn, D., J. Dushoff, S. A. Levin. 2002. Ecology and evolution of the flu. TRENDS Ecology Evolution 17(7) 334-340.
12. Federgruen, A., N. Yang. 2008. Selecting a portfolio of suppliers under demand and supply risks. Oper. Res. 56(4) 916-936.
13. General Accounting Office. 2001. Flu vaccine: Supply problems heighten need to ensure access for high-risk people. Report to Congressional Requesters, General Accounting Office, Washington, DC. http://www.gao.gov/new.items/d01624. pdf.
14. Health Industry Distributors Association. 2007. 2006-2007 influenza vaccine production and distribution, http://www.flusupplynews.com/documents/06- 07FluBrief.pdf-FINAL.pdf.
15. Hill, A. N., I. M. Longini. 2003. The critical vaccination fraction for heterogeneous epidemicmodels. Math. Biosciences 181(1) 85-106.
16. Jefferson, T., D. Rivetti, A. Rivetti, M. Rudin, C. Di Pietrantonj, V. Demicheli. 2005. Efficacy and effectiveness of influenza vaccines in elderly people: A systematic review. Lancet 366(9492) 1165-1174. (Pubitemid 41393594)
17. Kornish, L. J., R. L. Keeney. 2008. Repeated commit-or-defer decisions with a deadline: The influenza vaccine composition. Oper. Res. 56(3) 527-541.
18. Levandowski, R. A. 2005. Options for influenza composition 2005 - 2006. Presentation, Vaccines and Related Biological Products Advisory Committee, February 16-17, Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/ohrms/dockets/AC/05/slides/2005-4087S1-8.ppt.
19. Matthews, J. T. 2006. Egg-based production of influenza vaccine: 30 years of commercial experience. The Bridge 36(3) 17-24.
20. McCardle, K. F. 1985. Information acquisition and the adoption of new technology. Management Sci. 31(11) 1372-1389.
21. Morgan, L. O., R. M. Morgan, W. L. Moore. 2001. Quality and time-to-market trade-offs when there are multiple product generations. Manufacturing Service Oper. Management 3(2) 89-104.
22. Morris, W. T. 1968. Management Science: A Bayesian Introduction. Prentice-Hall, Upper Saddle River, NJ.
23. Nichol, K. L. 2003. The efficacy, effectiveness, and cost-effectiveness of inactivated infiuenza virus vaccines. Vaccine 21(16) 1769-1775.
24. O'Mara, D., K. Fukuda, J. A. Singleton. 2003. Infiuenza vaccine: Ensuring timely and adequate supply. Infect. Med. 20(11) 548-554.
25. Özer, Ö., O. Uncu. 2006. Optimizing dynamic time-to-market and production decisions for a component supplier. Working paper, Stanford University, Stanford, CA.
26. Philipson, T. 2003. Economic epidemiology and infectious diseases. A. J. Culyer, J. P. Newhouse, eds. Handbook of Health Economics, Vol.1B. Elsevier Science, Amsterdam, 1761-1799.
27. Sanofi Pasteur. 2005. Sanofi Pasteur awarded $97 million HHS contract to accelerate cell-culture pandemic infiuenza vaccine development. Press release (April 1).
28. Sanofi Pasteur. 2007. Sanofi Pasteur awarded contract to retrofit infiuenza vaccine facility. Press release (June 14).
29. Souza, G. C., B. L. Bayus, H. M. Wagner. 2004. New-product strategy and industry clockspeed. Management Sci. 50(4) 537-549.
30. Ulu, C., J. E. Smith. 2008. Uncertainty, information acquisition, and technology adoption. Oper. Res. 57(3) 740-752.
31. Vaccines and Related Biological Products Advisory Committee (Committee). 2002-2007. Transcripts and other meeting documents. Retrieved February 21, 2007, http://www.fda.gov/cber/advisory/vrbp/vrbpmain.htm.
32. Vaccines and Related Biological Products Advisory Committee (Committee). 2003. 94th Meeting (February 20). Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/ohrms/dockets/AC/03/transcripts/3922t1.doc.
33. Vaccines and Related Biological Products Advisory Committee (Committee). 2004. 97th Meeting (February 19). Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/ohrms/dockets/AC/04/transcripts/4020t2.doc.
34. World Health Organization. 2005. Influenza vaccines: WHO position paper. Weekly Epidemiological Record 33 277-288.
35. World Health Organization. 2007. Infiuenza. Retrieved February 21, 2007, http://www.who.int/immunization/topics/influenza/en/.
36. Wu, J. T., L. M.Wein, A. S. Perelson. 2005. Optimization of influenza vaccine selection. Oper. Res. 53(3) 456-476.
37. Yano, C. A, H. L. Lee. 1995. Lot sizing with random yields: A review. Oper. Res. 43(2) 311-334.